Medicon Valley Biomedical Newsletter

ALK-Abelló A/S and Menarini Group have signed an agreement for co-promotion, distribution and licensing of ALK-Abelló's tablet-based vaccine against grass pollen allergy, GRAZAX, and two coming ta...

Ambria Dermatology AB is an innovative Swedish R&D company with a patented technology platform providing pharmaceutical product concepts and product development opportunities in dermatology, cosme...

BioGaia AB has signed an agreement with one of the ten largest oral health companies in the world. The agreement gives the company exclusive rights to distribute under the customer's own b...

Cellcure A/S and Angel Biotechnology Holdings plc have announced a development and GMP manufacturing deal regarding clinical phase II trials. Angel is to manufacture and supply GMP materials fo...

Genmab A/S and GlaxoSmithKline have announced a worldwide agreement to co-develop and commercialize HuMax-CD20, a fully human monoclonal antibody in late stage development for CD20 positive B-cell chr...

Genmab A/S and Cytokine PharmaSciences Inc. have announced that Genmab has licensed rights to the MIF receptor target from Cytokine PharmaSciences. Genmab intends to develop therapeutic human antibodi...

Glycom ApS and Nestlé Nutrition have entered into an exclusive agreement on the research and development of human milk oligosaccharides, HMOs, for use in infant nutrition products. Scientific evidence...

H. Lundbeck A/S and Biotie Therapies Corp. have signed an agreement on worldwide rights for nalmefene, excluding North America, Mexico, UK, Ireland, Turkey, and South-Korea. Under the terms of the agr...

MIP Technologies AB has announced that it has signed an exclusive global distribution agreement with Supelco, for the distribution of analytical and preparative molecularly imprinted polymer, MIP, sep...

Novozymes A/S has announced that all conditions for the completion of the acquisition of GroPep Ltd. have now been fulfilled. The new name of the company will be Novozymes GroPep Ltd. The company will...

NsGene A/S has announced that an option agreement on NsG33, a novel neurotrophic protein, has been executed with Genzyme Corporation. Under this Option Agreement, Genzyme has been granted the exclusiv...

Nycomed A/S and Durect Corporation have announced the signing of a license agreement for Posidur, a long-acting and local pain relief depot for the treatment of post-surgical pain, currently in Phase ...

Osteologix A/S has announced the initiation of a Phase II clinical trial with a compound against osteoporosis. In the trial, 275 women in Denmark and England will be treated during three months with O...

Pharmexa A/S has treated the first patient in the HeptoVax Phase II trial of GV1001 in liver cancer, following receipt of the required approvals in France, Spain and Germany. The HeptoVax trial is a P...

Each year, 700,000 new cases of stroke occur in EU and of these, 30,000 are new cases in Sweden. In almost every second of the patients hospitalised with a neurological disease, the disease is caused ...

SchizoDetect Ltd. has developed a new method of support for diagnostic evaluation of schizophrenia. The need for such support is required in many areas of clinical psychiatry. Reported symptoms may du...

Symphogen A/S and the Japanese medical company Meiji Seika Kaisha Ltd have established a collaboration to use Symphogen's technology platform to develop, produce, and promote recombinant polyclona...

TopoTarget A/S and CuraGen have announced that the companies have reviewed interim efficacy and safety data from the ongoing open-label trial evaluating belinostat, PXD101, monotherapy for the treatme...